Search

Search Constraints

You searched for: Author/Creator Balwani, Manisha

Search Results

2. Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease. Issue 11 (5th September 2016)

3. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients With cholesteryl ester storage disease. Issue 3 (28th March 2013)

4. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. Issue 9 (11th July 2021)

6. Disease Characteristics of Acute Hepatic Porphyria Patients: ENVISION, a Phase 3 Global, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial: 996. (October 2019)

7. Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study. (16th November 2021)

8. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Issue 9985 (13th June 2015)

9. Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria. Issue 1 (14th September 2019)

10. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Issue 5 (7th November 2019)